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AbstrAct
Objectives To analyse patterns and characteristics 
of pharmaceutical industry sponsorship of events for 
Australian health professionals and to understand the 
implications of recent changes in transparency provisions 
that no longer require reporting of payments for food and 
beverages.
Design Cross-sectional analysis.
Participants and setting 301 publicly available company 
transparency reports downloaded from the website of 
Medicines Australia, the pharmaceutical industry trade 
association, covering the period from October 2011 to 
September 2015.
Results Forty-two companies sponsored 116 845 events 
for health professionals, on average 608 per week with 
30 attendees per event. Events typically included a broad 
range of health professionals: 82.0% included medical 
doctors, including specialists and primary care doctors, 
and 38.3% trainees. Oncology, surgery and endocrinology 
were the most frequent clinical areas of focus. Most events 
(64.2%) were held in a clinical setting. The median cost 
per event was $A263 (IQR $A153–1195) and over 90% 
included food and beverages.
Conclusions Over this 4-year period, industry-sponsored 
events were widespread and pharmaceutical companies 
maintained a high frequency of contact with health 
professionals. Most events were held in clinical settings, 
suggesting a pervasive commercial presence in everyday 
clinical practice. Food and beverages, known to be 
associated with changes to prescribing practice, were 
almost always provided. New Australian transparency 
provisions explicitly exclude meals from the reporting 
requirements; thus, a large proportion of potentially 
influential payments from pharmaceutical companies to 
health professionals will disappear from public view.
IntroductIon
Full disclosure of financial relationships 
between the pharmaceutical industry and 
health professionals is a key strategy adopted 
to make these interactions more transparent. 
Many jurisdictions have recently introduced 
transparency provisions, including the USA 
and the European Union, but the extent of 
the disclosure obligation varies. For example, 
meals and drinks fall outside the scope of 
disclosure obligations under new voluntary 
transparency provisions introduced by the 
European Federation of Pharmaceutical 
Industry Associations.1 At the same time, in 
the USA, over 100 medical societies recently 
backed a bill that would exempt pharmaceu-
tical and medical device companies from 
reporting an entire category of payments to 
doctors: those related to continuing medical 
education.2
Australia was one of the first countries 
to move towards public reporting of these 
payments. Since 2007, Medicines Australia, 
the trade association of the prescription 
medicines industry, has required member 
companies to provide detailed reports of 
sponsorship of events for health profes-
sionals, which include company-initiated 
events, sponsored events organised by a third 
party, trade displays at educational events and 
sponsorship of healthcare professionals to 
attend events both in Australia and overseas.3 
The reports are published on the Medicines 
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Research
Strengths and limitations of this study
 ► From publicly available reports released under 
Australian transparency rules, we have created a 
searchable world-first database with details of more 
than 100 000 industry-sponsored events for health 
professionals, enabling researchers to analyse 
the intersection of pharmaceutical marketing and 
medical education.
 ► In order to analyse the database, we iteratively 
identified a set of keywords for each variable of 
interest; however, it is possible that some synonyms 
were missed.
 ► We relied on data as presented in the Medicines 
Australia transparency reports, and we did not verify 
the accuracy and completeness of data.
 ► Transparency requirements apply only to member 
companies, excluding manufacturers of generics, 
over-the-counter and non-member prescription 
medicine manufacturers; thus, our analysis 
likely underestimates the true extent of industry 
sponsorship of events for health professionals.
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Australia website and include events for all registered 
healthcare professionals, making Australia one of the 
few countries with transparency extending to non-physi-
cians.4 5 These disclosure provisions were a condition for 
approval of Medicines Australia’s Code of Conduct by the 
Australian Competition and Consumer Commission and 
were upheld following a legal appeal by industry.6 Changes 
to this policy were introduced in 2015, with the focus on 
events replaced by disclosure of payments to individuals.3 
The reports detailing event sponsorship and aggregate 
payments to health professionals have been discontinued, 
and replaced with reports of payments to named individ-
uals, similar to the Open Payments database in the USA. 
Moreover, the new code no longer requires reporting of 
payments for food and beverages.
At a time when disclosure policies are being debated 
and revised in several settings,1–3 Australian data can 
provide valuable insights into patterns of industry spon-
sorship and on characteristics of transparency provisions 
that are needed to capture expenditures of pharmaceu-
tical companies on health professionals. Apart from two 
analyses of data from the first 6 months of the Australian 
disclosure scheme,4 7 and one brief report on events 
involving nurses,5 no comprehensive longer term anal-
yses have been conducted.
The objectives of this cross-sectional analysis are to 
describe the nature and frequency of events for health 
professionals sponsored by pharmaceutical companies 
that are members of Medicines Australia; to create an 
open-access searchable database of these events; and to 
estimate the information that will be lost under newly 
introduced reporting standards.
Methods
data sources
We downloaded all the available reports from the Medi-
cines Australia website (www. medicinesaustralia. com. 
au) in PDF format. The 301 PDF reports of approxi-
mately 15 000 pages covered the period October 2011 to 
September 2015. The PDFs had been originally created 
in Microsoft Excel. We requested the original Excel 
files from Medicines Australia but were refused on the 
basis that member companies had not given permission 
for their release. We converted the PDF files into Excel 
format using free, online converter programs, cleaned 
the data to address errors introduced during file conver-
sion, and ensured consistency of reporting in each 
column.
The reports cover information on the sponsoring 
company, timing, venue type, number and profession of 
participants, hospitality and travel for attendees, room 
rentals and equipment, and speaker honoraria.3
Over this 4-year period, 47 pharmaceutical compa-
nies issued transparency reports, and we grouped them 
based on mergers and acquisitions as of 31 March 2016. 
Therefore our analysis included 42 Medicines Australia 
member companies; as a frame of reference, there are 
approximately 140 separate companies listed as suppliers 
to the Australian Pharmaceutical Benefit Scheme.8
coding
We designed a coding scheme based on the available data 
and variables of theoretical interest based on the liter-
ature on industry–professional interactions9 10 and on 
two previous analyses of data from the first 6 months of 
the Australian disclosure scheme.4 7 The research team 
iteratively developed a set of keywords to define each vari-
able of interest (see online supplementary file 1). Using 
Excel’s filter function, we used the keywords to search the 
unstructured descriptive text and to dichotomously code 
event features as ‘present/absent’, for the following vari-
ables:
 ► sponsoring companies, grouped based on mergers 
and acquisitions as of 31 March 2016
 ► geographical location by Australian state or overseas 
location
 ► professional status of attendees (eg, specialists, nurses, 
trainees)
 ► clinical focus based on clinical specialty of attendees 
and event description (eg, oncology, endocrinology, 
cardiology)
 ► type of event (eg, journal club, workshop, in-services)
 ► type of hospitality provided (eg, breakfast, lunch, 
dinner).
statistical analysis
We present frequency tables for the characteristics of 
the events, and median spending levels per event and 
company. Cost variables are reported in Australian 
dollars. As the data were not normally distributed, we 
used Mann-Whitney U tests for the differences between 
medians. Analyses were performed using SPSS V.22.
results
General overview
From October 2011 to September 2015, 42 pharmaceu-
tical companies in Australia sponsored 116 845 events 
involving health professionals. On average, there were 
2434 events per month and 608 events per week. Each 
year, the number of events sharply decreased in December 
through February, likely reflecting the holiday season.
Table 1 provides illustrative examples of sponsored 
events as presented verbatim in the company reports, 
chosen to reflect variations in reporting and event type. 
Events varied greatly in scope and intensity, ranging from 
a half-hour journal club with sandwiches in a hospital 
meeting room, to a several-day conference with overseas 
flight, accommodation and hospitality provided. The 
professional status was sometimes described generically 
as ‘healthcare professionals’ or contained a list of the 
professions in attendees. The level of detail companies 
reported regarding the programme’s content and the 
extent of explicit product promotion also varied; most of 
the event descriptions were disease-focused (eg, ‘Journal 
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Club on Chronic Obstructive Pulmonary Disease’), but 
in some cases the events mentioned specific drug names 
(eg, ‘Introducing Zoely and other Emerging Trends in 
Contraception’).
Attendees
Over this 4 year period, there were 3 481 750 individual 
attendances at industry-sponsored events. The median 
number of event attendees was 18 (IQR 12–25); 97.2% 
(n=113 595) of the events had fewer than 100 attendees 
and 0.2% (n=210) had more than 1000 participants. 
Over 40% (n=47 084) of events included participants 
from multiple professions. Table 2 lists the professional 
status of attendees and the most frequent clinical areas of 
focus for the events. Events were most frequently oncolo-
gy-related, while otolaryngology and andrology were least 
represented.
location and characteristics of sponsored events
Three-quarters of events were held in the three Austra-
lian states with the largest populations — New South 
Wales (30.7%, n=35 888), Victoria (26.9%, n=31 448) and 
Queensland (18.8%, n=21 963) — and few were held over-
seas (1.9%, n=2262). Nearly two-thirds of events (64.2%, 
n=74 998) were held in a clinical setting, such as hospitals, 
clinics or doctors’ offices. Non-clinical venues included 
restaurants, hotels and convention centres. One-third of 
the events were described as a generic ‘meeting’ (37.5%, 
n=43 810), while others were described as journal clubs 
(28.5%, n=33 281), clinical meetings (3%, n=3533), 
grand rounds (3.8%, n=4472), in-services (2.6%, n=3038) 
or workshops (2.6%, n=3029). Only 4.2% (n=4290) were 
described as scientific meetings (eg, conferences or 
congresses).
costs and hospitality
Reporting companies spent $A286 117 928 on events 
for health professionals. On average, companies spent 
$A2449 per event (SD $A15 020), while the median cost 
was $A263 (IQR $A153–1195). The median cost per 
person was $A14 (IQR $A10–68). In 81.7% of the events 
(n=95 483), the costs were below $A100 per attendee, 
and in 2.1% (n=2438) the costs were over $A1000 per 
attendee.
Table 3 shows the median cost per person by charac-
teristics of events. The median total cost per person was 
significantly higher when the event format was a scientific 
meeting such as a congress or conference ($A93, IQR 
$A33–659) compared with other event types (p<0.001), 
for events held overseas ($A710, IQR $A91–7300) 
compared with events held in Australia (p<0.001), or 
outside the clinical settings ($A91, IQR $A28–154) as 
compared with events in the clinical setting (p<0.001).
Reported ‘hospitality or financial support’ provided 
to attendees included registration fees, travel, accom-
modation, parking and food and beverage. Food was 
provided at 90.4% (n=105 667) of events: 22.2% included 
lunches (n=25 935), 17.0% dinners (n=19 873), 12.0% 
teas (n=14 067), 11.0% breakfasts (n=12 806), 2.7% 
were all-day events with meals (n=3113), and for 25.6% 
(n=29 873) the type of food and beverage was unspeci-
fied. The total cost of food was more than $A84 million 
($A84 862 791), accounting for 29.7% of the total cost of 
these functions. However, for 65% (n=75 949) of events, 
the total listed cost for food and beverage was equal to the 
listed total cost of the event, indicating that the company’s 
sponsorship extended to food and beverage only. The 
median cost of food per person was $A12 (IQR $A8–20).
the top companies
Of the 42 pharmaceutical companies that provided 
reports, the top five in terms of the numbers of spon-
sored events were AstraZeneca, Novartis, Merck Sharp 
& Dohme, Roche and Pfizer (table 4). Boehringer Ingel-
heim had the highest cost per event, with a median cost 
of $A2007 (IQR $A1308–2654), while Eli Lilly spent the 
least with a median cost per function of $A145 (IQR 
$A62–455). Table 4 provides an overview of event spon-
sorship by the top 20 companies, representing 87.8% of 
events.
Availability of database
The analysable data set in CSV file format we have created is 
available at(http:// dx. doi. org/ 10. 4227/ 11/ 592631edbd-
9d5)(Direct link to the dataset: https:// research- data. 
sydney. edu. au/ index. php/ s/ npni79P4NhVQ0XB)
dIscussIon
Pharmaceutical industry-funded events for health profes-
sionals were frequent and pervasive, with almost three 
and a half million individual attendances at over 116 000 
events in the 4-year period between 2011 and 2015. As 
a frame of reference, in 2014 there were 610 148 regis-
tered health professionals in Australia,11 suggesting that 
there was wide exposure to these events. Events typically 
included a broad range of professionals and multidis-
ciplinary teams, including most commonly medical 
specialists, nurses, trainees and primary care doctors. 
Nearly two-thirds of events were held in clinical settings. 
Average costs per person were modest, and the vast 
majority of events (90.4%) included the provision of 
food and beverages. Additionally, for most events (65%), 
the only funding provided was for food and beverages. 
Thus, our analysis suggests that the new Australian and 
European transparency rules will decrease transparency 
because hospitality in the form of food and/or beverages 
will be exempt from reporting.1 3
Although professional education is critical for 
improving patient care, previous studies of internal 
pharmaceutical industry documents have shown 
that sponsored events have been effectively used as 
a marketing tool.12 13 A systematic review from 2010 
found that with rare exceptions, exposure to pharma-
ceutical industry information is associated with either 
no effect on prescribing or with adverse effects such as 
lower prescribing quality, higher frequency or costs.14 
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Table 2 Professional status of attendees and clinical areas 
of focus for the events (n=116 845)
Characteristics Number of events Per cent
Professional status of attendees*
  Medical specialists 80 060 68.5
  Nurses 46 214 39.6
  Trainees 44 774 38.3
  Primary care doctors 24 662 21.1
  Pharmacists 9781 8.4
Clinical areas of focus
  Oncology 22 987 19.7
  Surgery 13 306 11.4
  Endocrinology 12 655 10.8
  Cardiology 9033 7.7
  Haematology 8200 7.0
  Respiratory medicine 7659 6.6
  Psychiatry 6252 5.4
  Nephrology 6199 5.3
  Gastroenterology 5643 4.8
  Pathology 5361 4.6
  Neurology 4259 3.6
  Urology 4259 3.6
  Radiology 3667 3.1
  Infectious diseases 3348 2.9
  Geriatrics 3134 2.7
  Anaesthesiology 2746 2.4
  Rheumatology 2671 2.3
  Paediatrics 1994 1.7
  Allergy/Immunology 1398 1.2
  Ophthalmology 1365 1.2
  Palliative care 1319 1.1
  Intensive care 1147 1.0
  Sexual health 955 0.8
  Dermatology 913 0.8
  Obstetrics/Gynaecology 878 0.8
  Emergency 875 0.7
  Internal medicine 418 0.4
  Neonatology 363 0.3
  Nuclear medicine 357 0.3
  Pharmacology 219 0.2
  Otolaryngology 31 0.03
  Andrology 18 0.02
*Percentages do not add to 100 because multiple types of 
professionals could attend an event.
More recently, analyses of the Open Payments database 
in the USA have shown that payments for educational 
training and even the provision of low-cost free meals, 
commonly provided at sponsored events, are associated 
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Table 3 Characteristics of events and median cost per person
Number of events n=116 845, n (%) Median total cost per person* (IQR)
Location
  Overseas 2262 (1.9%) $A710 (91–7300)
  Within Australia 114 583 (98.1%) $A14 (10–62)
Setting
  Clinical setting 74 998 (64.2%) $A12 (9-15) 
  Non-clinical setting 41 847 (35.8%) $A91 (28–154)
Event type
  Scientific meeting (eg, congress, 
conferences)
4920 (4.2%) $A93 (33–659)
  Other types of events 111 925 (95.8%) $A14 (10–60)
*Includes hospitality as well as other costs (eg, venue hire, speaker honoraria, audiovisual hire).
Table 4 The top 20 companies in terms of number of sponsored events
Company
Number of 
events
Number of 
attendees
Total cost of food 
and beverage ($A)
Total cost of 
function* ($A)
Median total cost per 
event (IQR) ($A)
AstraZeneca 13 968 435 686 12 725 027 31 766 776 318 (165–2261)
Novartis 10 120 244 069 6 600 503 27 467 246 270 (167–1154)
Merck Sharp & Dohme 9142 214 621 5 388 247 18 352 116 341 (180–1182)
Roche 7383 174 878 2 891 426 16 625 126 186 (129–284)
Pfizer 7125 188 439 3 740 677 18 464 785 236 (141–573)
Sanofi 6764 261 089 3 243 420 13 668 127 240 (149–600)
Amgen 5562 117 767 4 545 874 11 145 245 192 (117–332)
Eli Lilly 5419 138 765 2 270 896 7 949 786 145 (62–455)
Servier Lab 4245 145 111 4 347 268 14 002 283 482 (196–2252)
Mundipharma 4168 135 517 2 956 613 8 939 046 342 (182–2394)
Janssen 3901 140 549 3 168 024 14 643 568 320 (164–1818)
GlaxoSmithKline 3706 103 331 2 993 037 6 292 242 254 (161–1645)
CSL 3285 138 170 1 337 909 6 000 501 288 (179–1427)
Bristol Myers Squibb 3151 138 446 2 492 290 12 755 630 245 (82–1900)
Bayer 2964 151 084 1 417 055 8 146 292 396 (194–1500)
IPSEN 2802 85 475 984 477 5 163 600 254 (169–454)
Abbott/AbbVie 2774 59 793 3 291 305 6 437 623 255 (157–1037)
Boehringer Ingelheim 2223 56 204 6 050 143 8 724 933 2007 (1308–2654)
Gilead Sciences 2049 45 510 990 419 7 061 338 245 (160–540)
Merck Serono 1841 41 809 1 376 023 4 237 372 229 (145–626)
Total – Top 20 102 592 3 016 313 72 810 634 247 843 635 262 (152–1199)
All companies 116 845 3 481 750 84 862 792 286 117 928 263 (153–1195)
*Includes food and drink, as well as other costs (eg, venue hire, speaker honoraria, audiovisual hire).
with increased prescribing of promoted, costly, brand-
name medications.15 16
Finally, we also found a high prevalence of trainee 
attendance at these events. Targeting medical trainees 
can lead to a process of normalisation and enculturation 
while trainees develop their professional identity.17 This 
has been described as an effective strategy ‘to influence 
physicians from the bottom up’.13 Medical school policies 
limiting trainee–industry interaction have been associ-
ated with a shift in attitude18 and reduced prescribing of 
costly new medicines without therapeutic advantages.19
Our study has a number of limitations. First, we relied 
on reports submitted by companies to Medicines Australia 
and could not verify the accuracy and completeness of 
data. Second, since the Code of Conduct’s transparency 
reporting requirements applies only to members of 
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Medicines Australia, the available reports likely underes-
timate the true extent of industry sponsorship of events 
for health professionals. Our analysis included only 42 
Medicines Australia member companies; as a frame of 
reference, approximately 140 manufacturers are listed 
as suppliers to the Australian Pharmaceutical Benefit 
Scheme.8 Moreover, non-member manufacturers of 
branded prescription medicines, generic medicines, 
over-the-counter medicines and medical devices are not 
covered by the Medicines Australia Code. Third, with 
regard to the coding scheme, the research team identi-
fied a set of keywords to define each variable of interest, 
and it is possible that some synonyms were missed due 
to variability in the data provided. Fourth, we did not 
assess the content of events due to the unstructured and 
variable nature of reporting. Fifth, our analysis focuses 
on industry sponsorship of events and did not examine 
differences in how event organisers manage potential 
influences. Finally, costs were not adjusted for inflation as 
these would likely have a limited impact on the Australian 
dollar over such a short time period. Notwithstanding 
these limitations, we have conducted a cross-sectional 
analysis of the only publicly available data on indus-
try-sponsored events for health professionals.
In conclusion, our findings have several international 
implications for future research and policy initiatives. 
While Australian transparency reports are difficult to 
analyse due to their format, we have created an open-ac-
cess, searchable, world-first database with details of 
more than 100 000 industry-sponsored events, enabling 
researchers to analyse the intersection of pharmaceutical 
marketing and medical education. Although the data 
included in this analysis are from Australia, pharmaceu-
tical companies are transnational corporations whose 
practices are likely to be similar across different coun-
tries. Moreover, individual institutions such as hospitals 
or universities may use these data to see what indus-
try-sponsored activities are happening within their own 
backyards, and whether they meet contemporary expec-
tations for transparency and independence.
At the policy level, at a time when new rules are being 
debated and revised globally, our findings underscore the 
need for more disclosure, not less. Transparency rules 
should be as inclusive as possible with regard to the type 
of companies required to report and also in terms of the 
scope of payments and categories of health professionals 
covered. The onus of reporting should not be on the 
industry only; for example, public sector hospitals as well 
as universities and professional associations could report 
meal subsidies from pharmaceutical and device manu-
facturers. A stronger policy option, already implemented 
at several academic medical centres in the USA, would 
be to eliminate the provision of free food by manufac-
turers.20 In the long term, ways of expanding funding for 
independent continuing professional education should 
be explored. There are already case studies showing that 
independence from industry sponsorship is achievable. 
For example the University of Michigan, as well as other 
major medical institutions in the USA, no longer accepts 
commercial support for continuing medical educa-
tion.21 22 This sets a valuable example that could become 
a model for other institutions. In the short term, univer-
sities and professional associations should make health 
professionals more aware of the independent sources of 
information on drugs that are already available (eg, NPS 
MedicineWise, the Australian Medicines Handbook and 
the independent drug bulletins).
Finally, our findings highlight that transparency 
requirements likely capture only a portion of industry 
sponsorship of events for health professionals. Changes 
to the transparency requirements will likely exacerbate 
this issue by excluding common categories of payments. 
Thus, decision-makers should be aware of the extent of 
industry-sponsored activity which will be hidden if ‘free 
food’ fails to be included in future transparency regimes.
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